
Geographic Atrophy Market Report and Forecast 2025-2034
Description
The geographic atrophy market was valued at USD 24.10 Billion in 2024, driven by the increasing prevalence of geographic atrophy and the rising regulatory approval of new therapeutic agents across the 8 major markets. The market is expected to grow at a CAGR of 5.70% during the forecast period of 2025-2034, with the values likely to reach USD 41.95 Billion by 2034.
Geographic Atrophy Market Overview
Geographic atrophy (GA) is the atrophic late form of age-related macular degeneration (AMD) and causes the destruction of retinal cells responsible for vision. It is reported to affect over 1 million individuals in the United States and around 5 million individuals globally. This progressive condition is predominantly found in older adults. Thus, as the aging population increases, the demand for the geographic atrophy market is expected to witness a surge.
The market is influenced by the growing awareness regarding this severe eye disease and its impact on vision. This is prompting more patients to seek early diagnosis and treatment. The growth in new drug approvals by regulatory bodies such as the FDA and EMA is also anticipated to aid in the market expansion. Moreover, factors such as significant investment in research and development in the retinal ophthalmology field, increased strategic partnerships among biotech and pharmaceutical companies, and advancements in diagnostic tools are expected to drive market growth.
Geographic Atrophy Market Growth Drivers
Increasing Prevalence of Geographic Atrophy Drives Market Growth
Recent data suggests that 1 out of 5 individuals aged 85 or more are affected by geographic atrophy in at least one eye. Bilateral geographic atrophy is reported to result in severe visual impairment, with a substantial burden on patients as well as healthcare providers. Although the prevalence and incidence of this eye disease varies across different regions, it is estimated that the highest burden of geographic atrophy is found in European ancestry. The increasing aging population is one of the primary drivers of the growing cases of this retinal disorder, which is anticipated to bolster market growth in the coming years.
Rise in Drug Approvals to Meet Rising Geographic Atrophy Market Demand
In February 2023, global biopharma company Apellis Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) granted approval to its drug SYFOVRE™ (pegcetacoplan injection) indicated for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulatory approval, based on the positive results from the Phase 3 OAKS and DERBY clinical studies, marked a milestone in the field of retinal ophthalmology, with SYFOVRE being the first FDA-cleared treatment for geographic atrophy. The rise in such regulatory approvals is set to fuel the market growth.
Geographic Atrophy Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growth in Strategic Partnerships
Many pharmaceutical companies are engaging in collaborations and acquisitions to accelerate the development of new treatments for retinal diseases including geographic atrophy. For instance, in December 2023, Japan-based Astellas Pharma Inc. completed the acquisition of United States biopharmaceutical company IVERIC Bio, Inc. to expand its portfolio in the ophthalmology disease segment.
Improvements in Diagnostic Technologies
The market is positively influenced by the improvements in diagnostic technologies, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF). The adoption of such advanced diagnostic tools is resulting in early detection and better monitoring of the disease, which is expected to boost the geographic atrophy market value._x000D_
Increased Investment in Research and Development
One of the major market trends is the growing R&D funding by pharmaceutical companies which is aimed at discovering and developing new treatments for geographic atrophy. Such substantial investments are helping in better understanding the disease and bringing effective therapies to the market._x000D_
Advancements in Drug Development
The market is benefitting from the development of new therapeutic agents that are reaching late-stage clinical trials. These drugs are designed to target the underlying mechanism of this severe retinal disease and show the potential for better management of the condition. The rising focus on biologics and gene therapy solutions to treat geographic atrophy is projected to aid market expansion.
Geographic Atrophy Market Segmentation
The EMR’s report titled “Geographic Atrophy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Age Group
Distribution Channel Segment is Projected to Fuel Market Growth
Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies cover a significant market share as they offer immediate access to medications for geographic atrophy in hospital settings. The online pharmacy segment is a growing market segment that allows patients to place orders for their medications remotely. Online pharmacies provide convenience and home delivery services and thus are gaining demand in the market.
Geographic Atrophy Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents a significant market share owing to the large population in the region affected by age-related macular degeneration (AMD), including geographic atrophy. The market growth is supported by increased access to advanced therapies and the presence of a positive regulatory environment that ensures faster market entry for new treatments.
Leading Players in the Geographic Atrophy Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Apellis Pharmaceuticals, Inc.
Based in Massachusetts, United States, Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company that is one of the leading players in the market. The company developed the first-ever treatment for geographic atrophy, SYFOVRE™ (pegcetacoplan injection), which the FDA approved in February 2023.
Iveric Bio
Iveric Bio, a part of Japan's Astellas Pharma, has a robust presence in the market and specializes in developing novel therapeutics for ophthalmic diseases. In August 2023, its therapy IZERVAY™ (avacincaptad pegol intravitreal solution) received FDA clearance for the treatment of geographic atrophy.
Alkeus Pharmaceuticals Inc.
United States-based Alkeus Pharmaceuticals Inc., a late-stage biopharmaceutical company, is known for developing therapies against serious and untreatable eye diseases. Its lead candidate Gildeuretinol acetate (ALK-001) is undergoing clinical development for geographic atrophy and Stargardt's disease.
Hemera Biosciences
Privately owned biotechnology company Hemera Biosciences is known for developing gene therapy to treat patients with age-related macular degeneration (AMD). The firm has developed drug candidate HMR59, a gene therapy designed to increase the expression of CD59, which has the potential to preserve vision in geographic atrophy patients.
Other key players in the market include Allegro Ophthalmics, Stealth BioTherapeutics, Novartis AG, Regenerative Patch Technologies, LLC, F. Hoffmann-La Roche AG, Gensight Biologics, NGM Biopharmaceuticals, AstraZeneca PLC, and Lineage Cell Therapeutics.
Key Questions Answered in the Geographic Atrophy Market Report
Geographic Atrophy Market Overview
Geographic atrophy (GA) is the atrophic late form of age-related macular degeneration (AMD) and causes the destruction of retinal cells responsible for vision. It is reported to affect over 1 million individuals in the United States and around 5 million individuals globally. This progressive condition is predominantly found in older adults. Thus, as the aging population increases, the demand for the geographic atrophy market is expected to witness a surge.
The market is influenced by the growing awareness regarding this severe eye disease and its impact on vision. This is prompting more patients to seek early diagnosis and treatment. The growth in new drug approvals by regulatory bodies such as the FDA and EMA is also anticipated to aid in the market expansion. Moreover, factors such as significant investment in research and development in the retinal ophthalmology field, increased strategic partnerships among biotech and pharmaceutical companies, and advancements in diagnostic tools are expected to drive market growth.
Geographic Atrophy Market Growth Drivers
Increasing Prevalence of Geographic Atrophy Drives Market Growth
Recent data suggests that 1 out of 5 individuals aged 85 or more are affected by geographic atrophy in at least one eye. Bilateral geographic atrophy is reported to result in severe visual impairment, with a substantial burden on patients as well as healthcare providers. Although the prevalence and incidence of this eye disease varies across different regions, it is estimated that the highest burden of geographic atrophy is found in European ancestry. The increasing aging population is one of the primary drivers of the growing cases of this retinal disorder, which is anticipated to bolster market growth in the coming years.
Rise in Drug Approvals to Meet Rising Geographic Atrophy Market Demand
In February 2023, global biopharma company Apellis Pharmaceuticals, Inc. announced that the United States Food and Drug Administration (FDA) granted approval to its drug SYFOVRE™ (pegcetacoplan injection) indicated for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulatory approval, based on the positive results from the Phase 3 OAKS and DERBY clinical studies, marked a milestone in the field of retinal ophthalmology, with SYFOVRE being the first FDA-cleared treatment for geographic atrophy. The rise in such regulatory approvals is set to fuel the market growth.
Geographic Atrophy Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Growth in Strategic Partnerships
Many pharmaceutical companies are engaging in collaborations and acquisitions to accelerate the development of new treatments for retinal diseases including geographic atrophy. For instance, in December 2023, Japan-based Astellas Pharma Inc. completed the acquisition of United States biopharmaceutical company IVERIC Bio, Inc. to expand its portfolio in the ophthalmology disease segment.
Improvements in Diagnostic Technologies
The market is positively influenced by the improvements in diagnostic technologies, such as optical coherence tomography (OCT) and fundus autofluorescence (FAF). The adoption of such advanced diagnostic tools is resulting in early detection and better monitoring of the disease, which is expected to boost the geographic atrophy market value._x000D_
Increased Investment in Research and Development
One of the major market trends is the growing R&D funding by pharmaceutical companies which is aimed at discovering and developing new treatments for geographic atrophy. Such substantial investments are helping in better understanding the disease and bringing effective therapies to the market._x000D_
Advancements in Drug Development
The market is benefitting from the development of new therapeutic agents that are reaching late-stage clinical trials. These drugs are designed to target the underlying mechanism of this severe retinal disease and show the potential for better management of the condition. The rising focus on biologics and gene therapy solutions to treat geographic atrophy is projected to aid market expansion.
Geographic Atrophy Market Segmentation
The EMR’s report titled “Geographic Atrophy Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Age Group
- 60-75 Years
- Above 75 Years
- Medications
- Supplements
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- United States
- EU-4 and the United Kingdom
- Japan
- India
Distribution Channel Segment is Projected to Fuel Market Growth
Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Hospital pharmacies cover a significant market share as they offer immediate access to medications for geographic atrophy in hospital settings. The online pharmacy segment is a growing market segment that allows patients to place orders for their medications remotely. Online pharmacies provide convenience and home delivery services and thus are gaining demand in the market.
Geographic Atrophy Market Analysis by Region
Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States represents a significant market share owing to the large population in the region affected by age-related macular degeneration (AMD), including geographic atrophy. The market growth is supported by increased access to advanced therapies and the presence of a positive regulatory environment that ensures faster market entry for new treatments.
Leading Players in the Geographic Atrophy Market
The key features of the market report comprise the patent analysis, clinical trial analysis, grant analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Apellis Pharmaceuticals, Inc.
Based in Massachusetts, United States, Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company that is one of the leading players in the market. The company developed the first-ever treatment for geographic atrophy, SYFOVRE™ (pegcetacoplan injection), which the FDA approved in February 2023.
Iveric Bio
Iveric Bio, a part of Japan's Astellas Pharma, has a robust presence in the market and specializes in developing novel therapeutics for ophthalmic diseases. In August 2023, its therapy IZERVAY™ (avacincaptad pegol intravitreal solution) received FDA clearance for the treatment of geographic atrophy.
Alkeus Pharmaceuticals Inc.
United States-based Alkeus Pharmaceuticals Inc., a late-stage biopharmaceutical company, is known for developing therapies against serious and untreatable eye diseases. Its lead candidate Gildeuretinol acetate (ALK-001) is undergoing clinical development for geographic atrophy and Stargardt's disease.
Hemera Biosciences
Privately owned biotechnology company Hemera Biosciences is known for developing gene therapy to treat patients with age-related macular degeneration (AMD). The firm has developed drug candidate HMR59, a gene therapy designed to increase the expression of CD59, which has the potential to preserve vision in geographic atrophy patients.
Other key players in the market include Allegro Ophthalmics, Stealth BioTherapeutics, Novartis AG, Regenerative Patch Technologies, LLC, F. Hoffmann-La Roche AG, Gensight Biologics, NGM Biopharmaceuticals, AstraZeneca PLC, and Lineage Cell Therapeutics.
Key Questions Answered in the Geographic Atrophy Market Report
- What was the geographic atrophy market value in 2024?
- What is the geographic atrophy market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on age group?
- What is the market breakup based on treatment?
- What is the market breakup by distribution channel?
- What are the major factors aiding the geographic atrophy market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence and incidence of geographic atrophy affect the market landscape?
- What are the major geographic atrophy market trends?
- How does the rise in the geriatric population impact the market size?
- Which age group will dominate the market share?
- Which treatment is expected to have a high market value in the coming years?
- Which distribution channel is projected to contribute to the highest market growth?
- Who are the key players involved in the geographic atrophy market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Geographic Atrophy Market Overview: 8 Major Market
- 3.1 Geographic Atrophy Market Historical Value (2018-2024)
- 3.2 Geographic Atrophy Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Geographic Atrophy Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Geographic Atrophy Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Geographic Atrophy Market Landscape: 8 Major Market*
- 8.1 Geographic Atrophy Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Geographic Atrophy Market: Product Landscape
- 8.2.1 Analysis by Treatment
- 9 Geographic Atrophy Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Geographic Atrophy: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Geographic Atrophy Market Segmentation: 8 Major Markets
- 12.1 Geographic Atrophy Market by Age Group
- 12.1.1 Market Overview
- 12.1.2 60-75 Years
- 12.1.3 Above 75 Years
- 12.2 Geographic Atrophy Market by Treatment
- 12.2.1 Market Overview
- 12.2.2 Medications
- 12.2.3 Supplements
- 12.2.4 Others
- 12.3 Geographic Atrophy Market by Distribution Channel
- 12.3.1 Market Overview
- 12.3.2 Hospital Pharmacy
- 12.3.3 Retail Pharmacy
- 12.3.4 Online Pharmacy
- 12.4 Geographic Atrophy Market by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Geographic Atrophy Market (218-2034)
- 13.1 United States Geographic Atrophy Market Historical Value (2018-2024)
- 13.2 United States Geographic Atrophy Market Forecast Value (2025-2034)
- 13.3 United States Geographic Atrophy Market by Age Group
- 13.3.1 Market Overview
- 13.3.2 60-75 Years
- 13.3.3 Above 75 Years
- 13.4 United States Geographic Atrophy Market by Treatment
- 13.4.1 Market Overview
- 13.4.2 Medications
- 13.4.3 Supplements
- 13.4.4 Others
- 13.5 United States Geographic Atrophy Market by Distribution Channel
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacy
- 13.5.3 Retail Pharmacy
- 13.5.4 Online Pharmacy
- 14 EU-4 and United Kingdom Geographic Atrophy Market (218-2034)
- 14.1 EU-4 and United Kingdom Geographic Atrophy Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Geographic Atrophy Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Geographic Atrophy Market by Age Group
- 14.3.1 Market Overview
- 14.3.2 60-75 Years
- 14.3.3 Above 75 Years
- 14.4 EU-4 and United Kingdom Geographic Atrophy Market by Treatment
- 14.4.1 Market Overview
- 14.4.2 Medications
- 14.4.3 Supplements
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Geographic Atrophy Market by Distribution Channel
- 14.5.1 Market Overview
- 14.5.2 Hospital Pharmacy
- 14.5.3 Retail Pharmacy
- 14.5.4 Online Pharmacy
- 15 Japan Geographic Atrophy Market
- 15.1 Japan Geographic Atrophy Market Historical Value (2018-2024)
- 15.2 Japan Geographic Atrophy Market Forecast Value (2025-2034)
- 15.3 Japan Geographic Atrophy Market by Age Group
- 15.3.1 Market Overview
- 15.3.2 60-75 Years
- 15.3.3 Above 75 Years
- 15.4 Japan Geographic Atrophy Market by Treatment
- 15.4.1 Market Overview
- 15.4.2 Medications
- 15.4.3 Supplements
- 15.4.4 Others
- 15.5 Japan Geographic Atrophy Market by Distribution Channel
- 15.5.1 Market Overview
- 15.5.2 Hospital Pharmacy
- 15.5.3 Retail Pharmacy
- 15.5.4 Online Pharmacy
- 16 India Geographic Atrophy Market
- 16.1 India Geographic Atrophy Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Geographic Atrophy Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Geographic Atrophy Market by Age Group
- 16.3.1 Market Overview
- 16.3.2 60-75 Years
- 16.3.3 Above 75 Years
- 16.4 India Geographic Atrophy Market by Treatment
- 16.4.1 Market Overview
- 16.4.2 Medications
- 16.4.3 Supplements
- 16.4.4 Others
- 16.5 India Geographic Atrophy Market by Distribution Channel
- 16.5.1 Market Overview
- 16.5.2 Hospital Pharmacy
- 16.5.3 Retail Pharmacy
- 16.5.4 Online Pharmacy
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Strategic Initiatives
- 21.1 Analysis by Partnership Instances
- 21.2 Analysis by Type of Partnership
- 21.3 Analysis by Leading Players
- 21.4 Analysis by Geography
- 22 Funding and Investment Analysis
- 22.1 Analysis by Funding Instances
- 22.2 Analysis by Type of Funding
- 22.3 Analysis by Funding Amount
- 22.4 Analysis by Leading Players
- 22.5 Analysis by Leading Investors
- 22.6 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Apellis Pharmaceuticals, Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Mergers and Acquisitions
- 23.2.5 Certifications
- 23.3 Iveric Bio
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Mergers and Acquisitions
- 23.3.5 Certifications
- 23.4 Alkeus Pharmaceuticals Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Mergers and Acquisitions
- 23.4.5 Certifications
- 23.5 Hemera Biosciences
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Mergers and Acquisitions
- 23.5.5 Certifications
- 23.6 Allegro Ophthalmics
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Mergers and Acquisitions
- 23.6.5 Certifications
- 23.7 Stealth BioTherapeutics
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Mergers and Acquisitions
- 23.7.5 Certifications
- 23.8 Novartis AG
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Mergers and Acquisitions
- 23.8.5 Certifications
- 23.9 Regenerative Patch Technologies, LLC
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 F. Hoffmann-La Roche AG
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic
- 23.10.4 Mergers and Acquisitions
- 23.10.5 Certifications
- 23.11 Gensight Biologics
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Mergers and Acquisitions
- 23.11.5 Certifications
- 23.12 NGM Biopharmaceuticals
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Mergers and Acquisitions
- 23.12.5 Certifications
- 23.13 AstraZeneca PLC
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Mergers and Acquisitions
- 23.13.5 Certifications
- 23.14 Lineage Cell Therapeutics
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Mergers and Acquisitions
- 23.14.5 Certifications
- 24 Geographic Atrophy Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.